Poor quality of life and impaired functioning across many symptom domains were shown in participants in the Real World Idiopathic Hypersomnia Outcomes Study (ARISE).
Burden of geographic atrophy high on patients, caregivers healio.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from healio.com Daily Mail and Mail on Sunday newspapers.
Long-term benefits of Vyepti® confirmed by new data presented at the annual meeting of the American Headache SocietyAn extension phase of the DELIVER study with Vyepti® (eptinezumab) demonstrated long-lasting migraine preventive effects with treatment for up to 18 months, reducing both frequency and severity.
/PRNewswire/ AbbVie (NYSE: ABBV) today announced that data from its robust migraine portfolio will be presented at the 16th European Headache Federation.